Skip to content

Serotonin: all studies

Page 144 of 400: studies 1,431 to 1,440 of 3,999, newest first. Back to the serotonin overview

Research

Modeling the Effects of Yoga on the Progression of Alzheimer's Disease in a Dish.

Cells, tissues, organs 2018 Adithy Hassan, Meghan Robinson, Stephanie M Willerth

Alzheimer's disease (AD) accounts for 80% of all dementia cases, making it the most common form of dementia. Aging serves as the main risk factor for AD, but early onset AD can also occur in individuals younger than 65 years. AD results from progressive neurodegeneration leading to dysfunctional synaptic transmission in the brain. The cascade hypothesis of AD states that amyloid precursor...

Inhibition of a Descending Prefrontal Circuit Prevents Ketamine-Induced Stress Resilience in Females.

eNeuro 2018 S D Dolzani, M V Baratta, J M Moss et al.

Stress is a potent etiological factor in the onset of major depressive disorder and posttraumatic stress disorder (PTSD). Therefore, significant efforts have been made to identify factors that produce resilience to the outcomes of a later stressor, in hopes of preventing untoward clinical outcomes. The NMDA receptor antagonist ketamine has recently emerged as a prophylactic capable of...

Reduced Efficacy of d-Amphetamine and 3,4-Methylenedioxymethamphetamine in Inducing Hyperactivity in Mice Lacking the Postsynaptic Scaffolding Protein SHANK1.

Frontiers in Molecular Neuroscience 2018 A Özge Sungur, Tobias M Redecker, Elena Andres et al.

Genetic defects in the three SH3 and multiple ankyrin repeat domains (SHANK) genes (SHANK1, SHANK2, and SHANK3) are associated with multiple major neuropsychiatric disorders, including autism spectrum disorder (ASD), schizophrenia (SCZ), and bipolar disorder (BPD). Psychostimulant-induced hyperactivity is a commonly applied paradigm to assess behavioral phenotypes related to BPD and considered...

Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances.

Handbook of experimental pharmacology 2018 Linda D. Simmler, Matthias E. Liechti

New psychoactive substances (NPS) with amphetamine-, aminoindan-, and benzofuran basic chemical structures have recently emerged for recreational drug use. Detailed information about their psychotropic effects and health risks is often limited. At the same time, it emerged that the pharmacological profiles of these NPS resemble those of amphetamine or 3,4-methylenedioxymethamphetamine (MDMA)....

The Discriminative Stimulus Properties of Hallucinogenic and Dissociative Anesthetic Drugs.

Current Topics in Behavioral Neurosciences 2018 Tomohisa Mori, Tsutomu Suzuki

The subjective effects of drugs are related to the kinds of feelings they produce, such as euphoria or dysphoria. One of the methods that can be used to study these effects is the drug discrimination procedure. Many researchers have been trying to elucidate the mechanisms that underlie the discriminative stimulus properties of abused drugs (e.g., alcohol, psychostimulants, and opioids). Over...

DOI: 10.1007/7854_2016_29 (opens in new tab) Full text (opens in new tab) Serotonin Discriminative stimulus properties Hallucinogens Psychedelics +1

Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems

European Journal of Pharmacology December 8, 2017 Dino Luethi, Marius C. Hoener, Matthias E. Liechti 41 citations

Diclofensine, diphenidine, and methoxphenidine are new psychoactive substances (NPSs) that recently appeared on the illicit drug market. Pharmacological profiling of such newly emerged drugs is crucial for a better understanding of their psychotropic effects and toxicity. We therefore investigated the potential of these NPSs to inhibit the norepinephrine, dopamine, and serotonin transporters in...

DOI: 10.1016/j.ejphar.2017.12.012 (opens in new tab) Monoaminergic Monoamine neurotransmitter Pharmacology Norepinephrine transporter +5

Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication

Psychopharmacology November 16, 2017 Eline Haijen, Magı́ Farré, Rafael de la Torre et al. 9 citations

Preclinical data have suggested involvement of the endocannabinoid (eCB) system in MDMA-induced memory impairment. Clinical research has shown that blockade of the 5-HT 2 receptor nulls memory impairment during MDMA intoxication. Interestingly, studies have demonstrated that the eCB and the 5-HT system interact. It was hypothesized that MDMA would cause an increase in eCB concentrations...

Fluorinated phenmetrazine “legal highs” act as substrates for high-affinity monoamine transporters of the SLC6 family

Neuropharmacology October 12, 2017 Felix P. Mayer, Nadine V. Burchardt, Ann M Decker et al. 30 citations

A variety of new psychoactive substances (NPS) are appearing in recreational drug markets worldwide. NPS are compounds that target various receptors and transporters in the central nervous system to achieve their psychoactive effects. Chemical modifications of existing drugs can generate NPS that are not controlled by current legislation, thereby providing legal alternatives to controlled...

DOI: 10.1016/j.neuropharm.2017.10.006 (opens in new tab) Serotonin Monoamine neurotransmitter Pharmacology Amphetamine +6

The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish

Frontiers in Psychiatry August 13, 2017 Luisa Ponzoni, Daniela Braida, Gianpietro Bondiolotti et al. 9 citations

3,4-methylenedioxymethamphetamine (MDMA) and its derivatives, 2,5-dimethoxy-4-bromo-amphetamine hydrobromide (DOB) and para-methoxyamphetamine (PMA) are recreational drugs whose pharmacological effects have recently been attributed to serotonin 5HT2A/C receptors. However, there is growing evidence that the oxytocin/vasopressin system can modulate some the effects of MDMA. In this study, MDMA...

Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen – Möglichkeiten und Hindernisse

Fortschritte der Neurologie · Psychiatrie July 1, 2017 Tomislav Majić, Henrik Jungaberle, Timo Torsten Schmidt et al. 10 citations

Zusammenfassung Hintergrund Der Einsatz von serotonergen Halluzinogenen (Psychedelika) wie Lysergsäure-Diethylamid (LSD) und Psilocybin und Entaktogenen wie 3,4-Methylendioxymethamphetamin (MDMA) im Rahmen von Psychotherapie ist in den letzten Jahren wieder zunehmend ins Licht des wissenschaftlichen Interesses gerückt. Die vorliegende Arbeit fasst die aktuelle Evidenz zur substanzunterstützten...